Skip to main content
MLAB
NASDAQ Industrial Applications And Services

Mesa Labs Issues First-Ever FY27 Guidance: $250-255M Revenue, $66-68M Adjusted EBITDA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Scientific Instrument Stocks · Technology
Sentiment info
Positive
Importance info
7
Price
$122
Mkt Cap
$715.264M
52W Low
$69.51
52W High
$144.35
52W Position info
76% above low
Off High info
15% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MLAB sits 76% above its 52-week low of $69.51.

Summary

Mesa Labs posted 77.6% operating income growth to $8.4M on 2.6% revenue growth and issued FY27 guidance for the first time: $250-255M revenue and $66-68M adjusted EBITDA. A new $40M buyback and a $9.3M savings plan underpin the margin story.


Key Events · Earnings and Guidance · MLAB

  • Q2 Operating Income Jumps 77.6%

    Revenue rose 2.6% to $62.336M while operating income climbed 77.6% to $8.388M. Diluted EPS was $0.75 versus $0.45 a year earlier, and adjusted EBITDA rose 21.1% to $17.317M, or 27.8% of revenues.

  • First-Ever FY27 Guidance Issued

    Management guided FY2027 to revenues of $250-255M and adjusted EBITDA of $66-68M, versus $62.969M of adjusted EBITDA in FY2026 — roughly 5-8% growth on 0-2% revenue growth. Q3 revenue is expected about flat year-over-year on lower Clinical Genomics sales.

  • New $40M Buyback Authorized

    On November 4, 2026 the board terminated the 2005 repurchase program and authorized up to $40.0M of buybacks through December 31, 2028, funded from cash on hand and operations. That sits alongside continued debt paydown of $11.406M in the quarter.

  • Savings Plan and Clinical Genomics Reshaping

    The October 13, 2026 plan targets ~$9.3M of annualized cost cuts with ~$4.3M reinvested for a net ~$5.0M reduction, at pre-tax charges of ~$2.6-3.4M. Clinical Genomics revenue fell 8.8% and is expected to keep declining as the business is managed for profitability rather than scale.


Analysis · MLAB · Industrial Applications And Services

The headline number is the first full-year guidance in company history: $250-255M revenue and $66-68M adjusted EBITDA, the latter up roughly 5-8% from FY26's $62.969M. That frames the story as margin repair and capital return rather than growth, and it lands alongside a new $40M buyback and a $9.3M savings plan. Q2 operating income jumped 77.6% to $8.4M on revenue of $62.3M, but management built the guidance conservatively on a half-year of data and flagged Q3 revenue as roughly flat because Clinical Genomics is being shrunk on purpose. Revenue growth of only 0-2% is the trade-off investors are being asked to accept.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLAB was trading at $122.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $715.3M. The 52-week trading range was $69.51 to $144.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLAB - Latest Insights

MLAB
Nov 09, 2026, 4:40 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $122.00
Real-time Price: $122.00 info
Change: $0 (0%) info
Market Cap: $715.264M info
MLAB
Nov 09, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $122.00
Real-time Price: $122.00 info
Change: $0 (0%) info
Market Cap: $715.264M info
MLAB
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $128.07
Real-time Price: $122.00 info
Change: -$6.07 (-5%) info
Market Cap: $715.264M info
MLAB
Oct 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $128.07
Real-time Price: $122.00 info
Change: -$6.07 (-5%) info
Market Cap: $715.264M info
MLAB
Aug 17, 2026, 11:49 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $108.36
Real-time Price: $122.00 info
Change: +$13.64 (+13%) info
Market Cap: $715.264M info